- ►diabetesjournals.org D Overkamp, A Volk, E Maerker, PE Heide, HG … - Diabetes care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Ten healthy, glucose-tolerant but insulin-resistant probands
were subjected to a placebo-controlled, double-blind, cross-over study. Each individual received
infusions of either 0.15 mol/l saline or glimepiride in randomized order on two separate ... Cited by 13 - Related articles - BL Direct - All 6 versions
G Charpentier, L Vaur, S Halimi, F Fleury, E … - Diabetes & metabolism, 2001 - cat.inist.fr Objectifs: L'objectif de DIAMETRE(D/abète et Amarel en Monothérapie. Etude de Titration pour
la définition des Répondeurs) était d'identifier les facteurs prédictifs de la réponse au glimépiride
en monothérapie chez le diabétique de type 2 au travers d'une étude prospective ... Cited by 8 - Related articles - BL Direct - All 2 versions
SB Simeonov, NP Botushanov, DA Iliev, HK Husianitis - Folia medica, 2002 - ncbi.nlm.nih.gov The purpose of the present study was to investigate the effect of the first third-generation sulphonylurea
drug glimepiride (Amaryl, Aventis) in the treatment of patients with type 2 diabetes mellitus in
an open 6-month clinical trial. The study included 19 patients with type 2 diabetes mellitus ... Cited by 4 - Related articles
MU Kabadi, UM Kabadi - Clinical therapeutics, 2004 - Elsevier Methods: This 24-week, open-label, controlled trial was conducted at the Division of Endocrinology
and Metabolism, Veterans Affairs Medical Center (Phoenix, Arizona). Study participants were
aged 32 to 75 years and had recent-onset (established by a short duration of symptoms 6 ... Cited by 14 - Related articles - All 3 versions
S Del Guerra, C Parentini, C Bracci, R Lupi, L Marselli, … - Acta Diabetologica, 2000 - Springer Sir: Glimepiride is a third-generation sulphonylurea drug that has been recently introduced to
treat patients with type 2 diabetes mellitus [1]. It has a short onset and a long dura- tion of
action, a blood glucose-lowering effect that is simi- lar to that of the other sulphonylureas, ... Cited by 4 - Related articles - BL Direct - All 3 versions
- ►diabetesjournals.org M Korytkowski, A Thomas, L Reid, MB Tedesco, WE … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—Glimepiride resulted in a 2.4-mmol/l decrease in fasting plasma glucose (P =
0.04) that was correlated with reductions in postabsorptive endogenous glucose production
(EGP) (16.4 ± 0.6 vs. 13.5 ± 0.5 μmol · kg −1 · min −1 , P = 0.01) (r = 0.21, P = 0.01). ... Cited by 44 - Related articles - BL Direct - All 5 versions
M Badian, A Korn, KH Lehr, V Malerczyk… - International journal of …, 1992 - ncbi.nlm.nih.gov 1: Int J Clin Pharmacol Ther Toxicol. 1992 Nov;30(11):481-2. Determination of the absolute
bioavailability of glimepiride (HOE 490), a new sulphonylurea. Badian M, Korn A, Lehr KH,
Malerczyk V, Waldhäusl W. Hoechst AG, Frankfurt/M, Germany. ... Cited by 7 - Related articles - BL Direct
CL Lawrence, RD Rainbow, NW Davies, … - British Journal of …, 2002 - pubmedcentral.nih.gov Glimepiride blocked pinacidil-activated whole-cell K ATP currents of cardiac myocytes with an
IC 50 of 6.8 nM, comparable to the potency of glibenclamide in these cells. Glimepiride blocked
K ATP channels formed by co-expression of Kir6.2/SUR2A subunits in HEK 293 cells in ... Cited by 8 - Related articles - BL Direct - All 4 versions
